Drug Trial Radar · NCT03780725
This Study Tests How BI 754111 is Distributed in Patients With Advanced Non-small Cell Lung Cancer or Patients With Head and Neck Cancer Who Are Treated With BI 754091
Last checked: Nov 19, 2026Latest source record: Jan 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
8
Actual
Start
Jan 22, 2019
Primary completion
Feb 19, 2020
Study completion Dec 8, 2020
Sponsor
- Lead sponsor
- Boehringer IngelheimBoehringer Ingelheim
- Sponsor type
- Industry
- First posted
- Dec 19, 2018
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The main objective of this study is to determine the biodistribution and intra-tumor accumulation of \[89Zr\]Zr-BI 754111 at baseline and its change upon treatment
Conditions
- Carcinoma, Non-Small-Cell Lung
- Head and Neck Neoplasms
Interventions
BI 754111Drug
Solution for infusion
[89Zr]Zr-BI 754111Drug
Solution for infusion
BI 754091Drug
Solution for infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Standard Uptake Value (SUV) in a 1ml Sphere Around Highest SUV Pixel (SUVpeak) of [89Zr]Zr-BI 754111 for Tumor Uptake - Part 1Time frame: At 96 hours and 144 hours post-injection of [89Zr]Zr-BI 754111 in each cycle.
- Standard Uptake Value (SUV) in a 1ml Sphere Around Highest SUV Pixel (SUVpeak) of [89Zr]Zr-BI 754111 for Tumor Uptake - Part 2Time frame: At 96 hours and 144 hours post-injection of [89Zr]Zr-BI 754111 in each cycle.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Amsterdam UMC Locatie VUMC
Amsterdam, Netherlands
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.